GTx-024 is an investigational drug.
There have been 35 clinical trials for GTx-024.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2011.
The most common disease conditions in clinical trials are Pancreatic Neoplasms, Prostatic Neoplasms, and Breast Neoplasms. The leading clinical trial sponsors are GTx, Columbia University, and National Cancer Institute (NCI).